← Human Trials & Peer-Reviewed Studies
Evaluation of Safety and Efficacy of Add-on Alpha-Lipoic Acid on Migraine Prophylaxis in an Adolescent Population: A Randomized Controlled Trial
Plain-language guide to PMID 37563914 (2023): double-blind randomized controlled trial study of CGRP (Calcitonin Gene-Related Peptide), migraine.
Key Facts
- PMID
- 37563914
- Journal
- Journal of clinical pharmacology
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Puliappadamb HM et al. (5 authors)
- DOI
- 10.1002/jcph.2331
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at CGRP (Calcitonin Gene-Related Peptide) in the context of migraine.
A clinical evaluation of the frequency and severity of migraine, responder rate, Pediatric Migraine Disability Assessment (PedMIDAS) scoring, serum thiol, and serum calcitonin gene-related peptide (CGRP) was performed both at baseline and following 12 weeks of treatment.
Who Took Part
By PubMed's age tags, the people studied were children and teenagers.
How the Study Was Run
The design is described as randomized, double-blind and open-label.
Random assignment meant chance, not the researchers, decided who got CGRP (Calcitonin Gene-Related Peptide) and who got the comparison, which limits bias.
As a double-blind CGRP (Calcitonin Gene-Related Peptide) study, the assignments were hidden from both participants and investigators until the end.
Being open-label, the CGRP (Calcitonin Gene-Related Peptide) study did not mask who received what.
A randomized, open-label, add-on clinical trial was conducted with 60 adolescent migraineurs, who were randomized to receive flunarizine or flunarizine with an add-on ALA.
What Was Measured
A clinical evaluation of the frequency and severity of migraine, responder rate, Pediatric Migraine Disability Assessment (PedMIDAS) scoring, serum thiol, and serum calcitonin gene-related peptide (CGRP) was performed both at baseline and following 12 weeks of treatment.
PubMed files the paper under topics including Flunarizine, Thioctic Acid, Calcitonin Gene-Related Peptide, Migraine Disorders, Analgesics and Sulfhydryl Compounds.
Author keywords: CGRP, PedMIDAS, adolescent migraine, alpha-lipoic acid and thiol.
What This Means in Plain Language
The paper is a randomized, double-blind and open-label study of CGRP (Calcitonin Gene-Related Peptide) in people with migraine.
The publication is from 2023 (Journal of clinical pharmacology), a journal based in England.
More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.
Our Notes on the Compound
CGRP (Calcitonin Gene-Related Peptide): A 37-amino-acid neuropeptide that widens blood vessels and is involved in migraine; given in research provocation studies.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.